Mounjaro vs Wegovy: How the Two Compare

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, this comparison is written for readers sorting a diabetes-first drug from a weight-first one. Browse the Peptides & GLP-1 Education Hub

This is an independent editorial comparison; PlexusDx has no commercial relationship with Eli Lilly or Novo Nordisk.

Mounjaro and Wegovy often appear in the same search, yet their FDA labels point in different directions from the start. As of April 2026, this comparison examines how each compound works, the trials behind each name, the side effects to expect, the sticker prices, and the genetics that apply across both.

A diabetes label meets a weight-management label

Mounjaro holds an FDA approval for type 2 diabetes granted in 2022, and its active ingredient is separately approved as Zepbound for weight management. Wegovy, by contrast, was FDA-approved in 2021 specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. That difference in indication drives prescribing and coverage more than any marketing claim.

How each compound engages the incretin system

Mounjaro is a GIP and GLP-1 dual receptor agonist from Eli Lilly; Wegovy is a selective GLP-1 receptor agonist from Novo Nordisk. Both act on the GLP-1 receptor in the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying and boosting satiety. Mounjaro adds agonism at the GIP receptor — the extra incretin arm that separates tirzepatide-based compounds from semaglutide-based ones.

Trial programs behind each name

Mounjaro was evaluated in the SURPASS program for glycemic and weight outcomes in type 2 diabetes, while Wegovy was evaluated in the STEP program for chronic weight management. Indirect comparisons exist between the SURMOUNT and STEP programs, and SURPASS tested tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Because populations and endpoints differ, the honest read stays at the per-trial level.

Side effects you can expect from both

Each carries the GLP-1 class boxed warning connected to thyroid C-cell tumor findings in rodent studies. Gastrointestinal symptoms lead the common side effects for both — nausea, vomiting, diarrhea, and constipation — and typically peak during dose escalation. Reported serious events across the class include pancreatitis, gallbladder events, and acute kidney injury linked to dehydration.

Sticker price and coverage realities

Mounjaro's U.S. list price is approximately $1,069 per month as of April 2026 (Eli Lilly published pricing), and Wegovy's is approximately $1,349 per month over the same window (Novo Nordisk published pricing). What lands on your bill depends on insurance coverage, manufacturer savings cards, the indication written on the prescription, and whether a compounded alternative is accessible through a licensed compounding pathway.

The upstream genetic terrain

Whichever a clinician prescribes, the genetic architecture underneath is shared. Variants in GIPR, GLP1R, FTO, and MC4R shape baseline appetite regulation, satiety signaling, and energy expenditure. They are pathway-level and do not predict response to Mounjaro or Wegovy, but they map the metabolic ground each compound works across. PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide Injection protocol. First, though, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — GIPR, GLP1R, FTO, and MC4R included — turning guesswork into an informed conversation with your provider.

More from the Hub: Wegovy subscription details, where to buy Wegovy, where to get Wegovy, and Wegovy and hypertension.

Editorial note: this article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols and covers here the mechanism, evidence, and genetic context behind any decision to use it. The Precision Peptide Genetic Test reflects how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Explore the formats in the Weight Management Protocols, or start upstream with the Precision Peptide Genetic Test. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

Is Wegovy only for weight loss and Mounjaro only for diabetes?

Wegovy's FDA approval is for chronic weight management, while Mounjaro's is for type 2 diabetes, though its active ingredient is separately approved as Zepbound for weight management. The label determines the on-label use and shapes coverage, so the indication written matters more than the brand name in a prescribing conversation.

Do the two share the same side-effect profile?

Broadly yes. Both are dominated by gastrointestinal symptoms that peak during dose escalation, and both carry the class-wide thyroid C-cell boxed warning from rodent studies. Tirzepatide products may show slightly higher rates of some GI symptoms in certain trials. Discuss your full history with a provider.

Where does the Precision Peptide Genetic Test fit in?

Upstream of the choice. It does not predict response to Wegovy, Mounjaro, or any medication; it reads pathway-level variants in GIPR, GLP1R, FTO, and MC4R that describe baseline GLP-1 and energy-balance biology — context that applies regardless of which compound is ultimately prescribed.

Why is Wegovy's list price higher?

Wegovy and Mounjaro are priced independently by different manufacturers, so their April 2026 list figures differ. List price, however, is rarely what a person pays; coverage, savings cards, the prescribed indication, and compounded-alternative availability usually influence the final cost far more than the headline number.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.